


# PARTNERS

A-TANGO is an international research project, spearheaded by EFCLIF, that brings together 14 partners from 8 European countries.



# A-TANGO IN A NUTSHELL

Full project title	Novel treatment of acute-on-chronic liver failure (ACLF) using synergistic action of G-CSF and TAK-242
Start date	1 <sup>st</sup> March 2021
Duration	5 years
Participants	14 institutions from 8 countries
EC funding	6 million €

Project website

[www.a-tango.eu](http://www.a-tango.eu)

# CONTACT

Scientific coordinator	Prof. Dr. Rajiv Jalan (EFCLIF & UCL) rajiv.jalan@efclif.com
Clinical study supervisor	Dr. med. Cornelius Engelmann (CHARITÉ) clinicalstudy@atango.eu
Project management	concentris research management gmbh info@atango.eu

Follow A-TANGO on social media

[Twitter](#)

[LinkedIn](#)

[ResearchGate](#)

[YouTube](#)



This project has received funding from the European Union's Horizon2020 research and innovation programme under grant agreement No 945096. The folder reflects only the authors' view and the European Commission is not responsible for any use that may be made of the information it contains.



## OUR VISION

More than 10 million people worldwide suffer from decompensated cirrhosis. In its final stages, decompensated cirrhosis leads to acute-on-chronic liver failure (ACLF), a syndrome characterised by systemic inflammation, fluid accumulation in the abdomen (ascites), impaired brain function (hepatic encephalopathy), internal bleeding (gastro-intestinal haemorrhage), and multi-organ failure, often leaving liver transplantation as the last resort to save the patient's life. Therefore, effective treatment of ACLF remains an urgent and unmet need.

The A-TANGO consortium performs Phase 2 clinical studies of a novel and innovative

combinatorial therapy that aims to improve hepatocyte proliferation through granulocyte colony-stimulating factor (G-CSF) and to reduce systemic inflammation by repurposing TAK-242, an antagonist of toll-like receptor 4. We call this novel combinatorial therapy "G-TAK". In addition, A-TANGO strives to identify reliable biomarkers for better patient stratification and increased survival. Up to 25 liver centres in Europe are participating in the clinical study.

Our vision is to drastically reduce the mortality rate of end-stage liver disease and to improve the prognosis, life expectancy, and quality of life of cirrhosis patients.


**G-TAK = G-CSF + TAK-242**

**25 hospitals across Europe planned to participate in the clinical G-TAK study!**

## OUR OBJECTIVES

- Obtain **ethical and regulatory approval** of the planned clinical studies and ensure safe and regulated supply of the required drugs and placebos
- Successfully conduct the **multicentre G-TAK study** in 25 European hospitals to establish the safety, pharmacokinetics, and efficacy of our novel combinatorial therapy
- Explore the pathophysiological mechanisms and **potential biomarkers** and evaluate our results with respect to clinical outcome, treatment impact, and quality of life
- **Exploit our results** by identifying economic benefits for the healthcare system, reimbursement strategies, and potential commercial interest
- **Disseminate the therapeutic potential** of our novel treatment strategy to stakeholders and increase awareness of end-stage liver disease

## EXPECTED IMPACT



**A-TANGO strives to increase patient survival & reduce the immense healthcare burden**